Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Totally agree with you......
This is a very strange stock
This move needs follow up news or another good leg up or we drift right back.
Not in the public domain..........
I was wondering myself at the rise today as I can see no reason for it. Perhaps some insiders know something we don't and have let it slip to the tutes....
Today it’s up with high volume. All that’s out is data update in June with posters. Doesn’t seem like big enough news to cause a morning spike of 1mil+ shares. Is there something else brewing?
50 cent jump in Premarket....
I wonder why?
Rise up to 1.7 yesterday now back down. This slow weekly bleed needs to be plugged.
That's what I can't understand, all time lows - that means EVERYONE would be selling at a loss.
At this rate we will be at 10 year low next week
What’s going on with this one. Another sharp drop today
It's a 10k of jibber jabber, but there was some info i hadn't seen in their agreement with Haichang. Didn't we read this trial will have initial results this year? That would be a good indicator if Haichang would potentially exercise their exclusive license. So unless the U.S. Goes to war with China, we may get some funding next year......
Haichang will fund all development activities through completion of the Phase 2a clinical trial up to an aggregate amount of $10,000,000 and the parties will share downstream licensing fees and royalties paid by third parties in an agreed ratio in connection with the further development and commercialization of RX-0201 for the treatment of HCC. If Haichang exercises its right of first negotiation after completion of the Phase 2a clinical trial to obtain an exclusive license to further develop and commercialize RX-0201 in China, Haichang will pay customary license fees, milestone payments and royalties to Rexahn. Any clinical trials conducted by Haichang will be designed to meet both FDA and China Food and Drug Administration requirements.
What’s your opinion on the recent 10k filed today?
We were sitting at all time lows, I've been in this clam for 7 years. Makes me sad when I think about it.....regardless, who would be selling at those prices?
Welcome back to the 1.70’s... volume is picking up.
Heavy volume at the end of the day and the price didn't move. Has the smell of manipulation but who knows, surely not us.
Either being heavily manipulated down & will be manipulated back up, or the street doesn’t believe management’s enthusiasm
I'm a patient person but this is ridiculous, .16 seriously...
Seven stars cloud great buy in right now.
I like the chart and I just got in at $1.75. $12 plus price targets on both Yahoo and Market Watch. And the pipeline looks good as I posted it in the previous post. With quarterly due out soon, I am hoping this "multiple bottom 6 month pattern" chart that I like holds through the report and then we get some upwards action?
I know we have fallen off a cliff lately, but maybe this 3rd "multiple bottom" could be our final bottom?
Or not?
LOL
Good luck to all.
I don't know if the MM's are stalling movement on this or retail simply does not like this stock. I don't understand the lack of volume given the news. It's possible the absence of details regarding the "partnership" has people waiting. Mentions of royalties and milestone payments but no details. Let's go RNN PR department.....
Data looks good. Do shorts begin covering....???
Week In Review: Tsinghua University Invests $276 Million In Cambridge U.K. Biohub http://www.seekingalpha.com/article/4145465
Zhejiang Haichang Biotechnology - anyone find any good details on this Chinese company rexahn is partnering with? Not much info about them at all. Website http://m.lanbobio.com
When will this bio bloodbath end??
Rexahn Pharmaceuticals' RX-3117 could be a blockbuster, says HC Wainwright
Rexahn Pharmaceuticals RX-3117 could be a blockbuster
RNN hasn't updated their pipeline on their own website. I like the products, marketing needs some help.
Data always looks good but here we are $.24 - good to see some volume and a little price movement. Need a partnership.....nothing else will move this significantly. I can't see MM's letting this go without big pharma in RNN's pockets.
They presented data from the Phase II Rx-3117 in Advanced Pancreatic cancer
Data does look encouraging
http://files.shareholder.com/downloads/AMDA-2J9T0P/5897818201x0x969037/C86E1B27-6BE6-4DED-B6ED-1D5E1E15F893/2018_January_ASCO_GI_RX-3117_FINAL.PDF
just anticipation of news moving this. Anything can happen even a halt when the actually news is released
news leak??News must be good! Are we going see a mega short squeeze???Sure hope so!!
Let us just hope.....
That the people below know something we don't know ;)
RNN PT Raised
Well I was just posting as something is finally happening. One could say this is coming half a year late on their 2Q/3Q 2017 guidance for the data read out.
While it will be good to see something positive I'm not expecting much to happen for the PPS. I mean we are still not close to making revenue, no clear partnerships being announced, (hopefully good phase II data can help with this), and as far as biotech investing is concerned, generally no-one really cares about Phase II data in a pre-revenue company, unless the phase II really knocks it out of the park. They'll wait out till at least close to phase III data and get in then, as in the meantime it will still mean cash burn and likely dilution till the proof that the FDA will allow to sell the product.
But still looking forward to any good news they can give and hoping for more soon as they have other missed guidance which hopefully like this needed just a little extra time.
Saddle up Belus!
This is one of the moments we have been waiting patiently for.
GLTA
About Time :)
I have been sitting patiently waiting for this.
Notice the times of the sessions? I wonder if they are going to present whilst the main market is still open or wait for the after-market session?
Expecting some good action either way.
GLTA!!!
Rexahn today to present Phase IIa RX-3117 data on Pancreatic Cancer
https://globenewswire.com/news-release/2018/01/18/1296413/0/en/Rexahn-Pharmaceuticals-to-Present-at-the-American-Society-of-Clinical-Oncology-Gastrointestinal-Cancers-ASCO-GI-2018-Annual-Meeting.html
Working for now, Q1 data will be the tell.GLTA
Holding good here from 2.00+.
That's ok, we're on the side of the road. Change them tires, splash her up and we'll be moving.
This one rarely holds gains in the long run. Strategy is usually to sell on the yearly pops
I think the same thing, Lots of spikes but holding for the run of news, progress and approvals he he he he, You really have to do you homework on this one. Peace Belus
Looking at a Great Year for Rexahn Phamra, Earnings out soon, which will be in the Green. More trials coming out which will boost the PPS even more, I would think we will be between 5 to 7 a share soon. With an FDA approval about 23 to 24, That would be an Awesome 2018,
Will just have to see, GLTA,
Peace, Belus
Low volume, quiet beginning to 2018. Should make an interesting year for Rexahn
Followers
|
192
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3898
|
Created
|
06/17/08
|
Type
|
Free
|
Moderators |
http://www.rexahn.com/cms/
http://finance.yahoo.com/q/ks?s=RNN
Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.
Our clinical development pipeline consists of three novel compounds:
RX-3117 is a novel, oral, small molecule nucleoside compound. Once intracellularly activated (phosphorylated) by the enzyme UCK2, it is incorporated into the DNA or RNA of cells and inhibits both DNA and RNA synthesis, which induces apoptotic cell death of tumor cells. Because UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues, RX-3117 offers the potential for a targeted anti-cancer therapy with an improved efficacy and safety profile, and we believe it has therapeutic potential in a broad range of cancers, including pancreatic, bladder, colon, and lung cancer. RX-3117 has received “orphan drug designation” from the U.S. Food and Drug Administration (“FDA”) and from the European Commission (“EC”) for pancreatic cancer.
RX-5902 (Supinoxin™) is a potential first-in-class small molecule inhibitor of phosphorylated-p68, a protein that we believe plays a key role in cancer cell growth, progression and metastasis through its interaction with beta-catenin. Phosphorylated p68, which is highly expressed in cancer cells, but not in normal cells, results in up-regulation of cancer-related genes and a subsequent proliferation of cancer cells and tumor growth. RX-5902 selectively blocks the interaction of phosphorylated p68 with beta-catenin, thereby decreasing the proliferation or growth of cancer cells in preclinical models. In addition, multiple pre-clinical models suggest that RX-5902 enhances the efficacy of immunotherapy. We have evaluated RX-5902 in a Phase 1 dose escalation study in patients with a diverse range of metastatic, treatment-refractory tumors, including breast, ovarian, colorectal, and neuro-endocrine tumors. In February 2017, we initiated a Phase 2a clinical study of RX-5902 in patients with metastatic triple negative breast cancer (“TNBC”).
RX-0201 (Archexin®) is a potential best-in-class, potent inhibitor of the protein kinase Akt-1, which we believe plays a critical role in cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-0201 is the subject of a research and development collaboration with Zhejiang Haichang Biotechnology Co., Ltd. (“Haichang”) for the development of RX-0201 for hepatocellular carcinoma. RX-0201 has received orphan drug designation from the FDA for renal cell carcinoma (“RCC”), glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer.
These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.
Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.
Rexahn Pipeline
Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.
Rick Soni, MBA
President and Chief Operating Officer
Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.
Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President and Chief Financial Officer
Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University
ANALYST COVERAGE
Roth Capital Partners, LLC
Joseph Pantginis, Ph.D.
646-358-1907
jpantginis@roth.com
Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718
ehe@maximgrp.com
H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546
afein@hcwco.com
INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |